Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

Shots:

• Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer
• BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene
• In April, 2015 Myriad and AstraZeneca also entered into agreement for evaluating Lynparza in patients with metastatic pancreatic cancer using Myriad’s BRACAnalysis CDx test

Click here to read full press release/ article | Ref: Myriad | Image: Forbes